Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab monotherapy in first recurrent glioblastoma (Japan, ONO-4538-19)
jRCT2080222915Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in glioblastoma (GBM), Gliosarcoma (GS) and malignant glioma, sponsored by Ono Pharmaceutical. Primary endpoint: 1-year overall survival. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)malignant glioma
Beyond the preview
Go deeper on jRCT2080222915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222915.